These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility. Goldman RC; Laughon BE; Reynolds RC; Secrist JA; Maddry JA; Guié MA; Poffenberger AC; Kwong CA; Ananthan S Infect Disord Drug Targets; 2007 Jun; 7(2):92-104. PubMed ID: 17970221 [TBL] [Abstract][Full Text] [Related]
8. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model. Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471 [TBL] [Abstract][Full Text] [Related]
9. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem. Goldman RC Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384 [TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of new antitubercular compounds as potential drug leads and probes. Goldman RC; Laughon BE Tuberculosis (Edinb); 2009 Sep; 89(5):331-3. PubMed ID: 19716767 [TBL] [Abstract][Full Text] [Related]
12. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046 [No Abstract] [Full Text] [Related]
13. The future for early-stage tuberculosis drug discovery. Zuniga ES; Early J; Parish T Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534 [TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494 [TBL] [Abstract][Full Text] [Related]
17. Parallel synthesis of chiral pentaamines and pyrrolidine containing bis-heterocyclic libraries. Multiple scaffolds with multiple building blocks: a double diversity for the identification of new antitubercular compounds. Nefzi A; Appel J; Arutyunyan S; Houghten RA Bioorg Med Chem Lett; 2009 Sep; 19(17):5169-75. PubMed ID: 19632841 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006 [TBL] [Abstract][Full Text] [Related]
19. Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis. Makane VB; Krishna VS; Krishna EV; Shukla M; Mahizhaveni B; Misra S; Chopra S; Sriram D; Azger Dusthackeer VN; Rode HB Future Med Chem; 2019 Mar; 11(6):499-510. PubMed ID: 30892944 [TBL] [Abstract][Full Text] [Related]